Skip to main content
Journal cover image

Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).

Publication ,  Journal Article
Vaduganathan, M; Greene, SJ; Ambrosy, AP; Mentz, RJ; Fonarow, GC; Zannad, F; Maggioni, AP; Konstam, MA; Subacius, HP; Nodari, S; Butler, J ...
Published in: Am J Cardiol
December 1, 2013

Serum magnesium levels may be impacted by neurohormonal activation, renal function, and diuretics. The clinical profile and prognostic significance of serum magnesium level concentration in patients hospitalized for heart failure (HF) with reduced ejection fraction is unclear. In this retrospective analysis of the placebo group of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan trial, we evaluated 1,982 patients hospitalized for worsening HF with ejection fractions ≤40%. Baseline magnesium levels were measured within 48 hours of admission and analyzed as a continuous variable and in quartiles. The primary end points of all-cause mortality (ACM) and cardiovascular mortality or HF rehospitalization were analyzed using Cox regression models. Mean baseline magnesium level was 2.1 ± 0.3 mg/dl. Compared with the lowest quartile, patients in the highest magnesium level quartile were more likely to be older, men, have lower heart rates and blood pressures, have ischemic HF origin, and have higher creatinine and natriuretic peptide levels (all p <0.003). During a median follow-up of 9.9 months, every 1-mg/dl increase in magnesium level was associated with higher ACM (hazard ratio [HR] 1.77; 95% confidence interval [CI] 1.35 to 2.32; p <0.001) and the composite end point (HR 1.44; 95% CI 1.15 to 1.81; p = 0.002). However, after adjustment for known baseline covariates, serum magnesium level was no longer an independent predictor of either ACM (HR 0.94, 95% CI 0.69 to 1.28; p = 0.7) or the composite end point (HR 1.01, 95% CI 0.79 to 1.30; p = 0.9). In conclusion, despite theoretical concerns, baseline magnesium level was not independently associated with worse outcomes in this cohort. Further research is needed to understand the importance of serum magnesium levels in specific HF patient populations.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

December 1, 2013

Volume

112

Issue

11

Start / End Page

1763 / 1769

Location

United States

Related Subject Headings

  • Stroke Volume
  • Retrospective Studies
  • Proportional Hazards Models
  • Prognosis
  • Patient Readmission
  • Patient Discharge
  • Myocardial Ischemia
  • Middle Aged
  • Male
  • Magnesium
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vaduganathan, M., Greene, S. J., Ambrosy, A. P., Mentz, R. J., Fonarow, G. C., Zannad, F., … EVEREST Trial Investigators. (2013). Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). Am J Cardiol, 112(11), 1763–1769. https://doi.org/10.1016/j.amjcard.2013.07.020
Vaduganathan, Muthiah, Stephen J. Greene, Andrew P. Ambrosy, Robert J. Mentz, Gregg C. Fonarow, Faiez Zannad, Aldo P. Maggioni, et al. “Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).Am J Cardiol 112, no. 11 (December 1, 2013): 1763–69. https://doi.org/10.1016/j.amjcard.2013.07.020.
Vaduganathan M, Greene SJ, Ambrosy AP, Mentz RJ, Fonarow GC, Zannad F, et al. Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). Am J Cardiol. 2013 Dec 1;112(11):1763–9.
Vaduganathan, Muthiah, et al. “Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).Am J Cardiol, vol. 112, no. 11, Dec. 2013, pp. 1763–69. Pubmed, doi:10.1016/j.amjcard.2013.07.020.
Vaduganathan M, Greene SJ, Ambrosy AP, Mentz RJ, Fonarow GC, Zannad F, Maggioni AP, Konstam MA, Subacius HP, Nodari S, Butler J, Gheorghiade M, EVEREST Trial Investigators. Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). Am J Cardiol. 2013 Dec 1;112(11):1763–1769.
Journal cover image

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

December 1, 2013

Volume

112

Issue

11

Start / End Page

1763 / 1769

Location

United States

Related Subject Headings

  • Stroke Volume
  • Retrospective Studies
  • Proportional Hazards Models
  • Prognosis
  • Patient Readmission
  • Patient Discharge
  • Myocardial Ischemia
  • Middle Aged
  • Male
  • Magnesium